evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

17 questions · 18 findings · 3 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2 · 11.1%GRADE not reported 0 · 0%Very low 12 · 66.7%Low 4 · 22.2%Moderate 0 · 0%High 0 · 0%

Active drain vs passive drain

Intra‐abdominal infection · people undergoing elective pancreatic resections

It is very uncertain whether active drain changes intra‐abdominal infection compared with passive drain following pancreatic surgery (very low certainty).

1 finding from 1 review

Active drain vs passive drain

Length of hospital stay · people undergoing elective pancreatic resections

It is very uncertain whether active drain changes length of hospital stay compared with passive drain following pancreatic surgery (very low certainty).

1 finding from 1 review

Active drain vs passive drain

All‐cause mortality · people undergoing elective pancreatic resections

It is very uncertain whether active drain changes mortality compared with passive drain following pancreatic surgery (very low certainty).

2 findings from 1 review

Infliximab 5 mg/kg vs infliximab 10 mg/kg

Clinical remission defined as absence of any draining fistulas at ≥ 2 consecutive visits, at a median 12 weeks · Patients with active Crohn's disease

It is very uncertain whether infliximab 5 mg/kg changes clinical remission defined as absence of any draining fistulas at ≥… compared with infliximab 10 mg/kg (very low certainty).

1 finding from 1 review

Infliximab 5 mg/kg vs infliximab 10 mg/kg

Clinical response defined as reduction of 50% in the number of draining fistula at ≥ 2 consecutive visits, at a median length of time of 12 weeks · Patients with active Crohn's disease

It is very uncertain whether infliximab 5 mg/kg changes clinical response defined as reduction of 50% in the number of… compared with infliximab 10 mg/kg (very low certainty).

1 finding from 1 review

Infliximab 5–10 mg/kg vs placebo

Clinical remission defined as absence of any draining fistulas at ≥ 2 consecutive visits, at a median 12 weeks · Patients with active Crohn's disease

It is very uncertain whether infliximab 5–10 mg/kg changes clinical remission defined as absence of any draining fistulas at ≥… compared with placebo (very low certainty).

1 finding from 1 review

Infliximab 5–10 mg/kg vs placebo

Clinical response defined as reduction of 50% in the number of draining fistula at ≥ 2 consecutive visits, at a median length of time of 12 weeks · Patients with active Crohn's disease

It is very uncertain whether infliximab 5–10 mg/kg changes clinical response defined as reduction of 50% in the number of… compared with placebo (very low certainty).

1 finding from 1 review